A detailed history of State Street Corp transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, State Street Corp holds 3,818,320 shares of LYEL stock, worth $4.66 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,818,320
Previous 3,717,963 2.7%
Holding current value
$4.66 Million
Previous $8.29 Million 33.23%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.3 - $3.01 $130,464 - $302,074
100,357 Added 2.7%
3,818,320 $5.54 Million
Q1 2024

May 15, 2024

BUY
$1.71 - $3.07 $305,879 - $549,152
178,877 Added 5.05%
3,717,963 $8.29 Million
Q4 2023

Feb 14, 2024

SELL
$1.39 - $2.35 $4.55 Million - $7.69 Million
-3,271,342 Reduced 48.03%
3,539,086 $6.87 Million
Q3 2023

Nov 14, 2023

BUY
$1.45 - $3.35 $926,815 - $2.14 Million
639,183 Added 10.36%
6,810,428 $10 Million
Q2 2023

Aug 14, 2023

SELL
$1.89 - $3.86 $3.31 Million - $6.76 Million
-1,750,007 Reduced 22.09%
6,171,245 $19.6 Million
Q1 2023

May 15, 2023

SELL
$1.97 - $3.58 $1.63 Million - $2.97 Million
-829,167 Reduced 9.48%
7,921,252 $18.7 Million
Q4 2022

Feb 14, 2023

BUY
$2.78 - $8.09 $9.37 Million - $27.3 Million
3,370,581 Added 62.65%
8,750,419 $30.4 Million
Q3 2022

Nov 15, 2022

BUY
$5.54 - $8.27 $15.4 Million - $23 Million
2,783,919 Added 107.24%
5,379,838 $39.4 Million
Q2 2022

Aug 15, 2022

BUY
$3.68 - $6.8 $2.59 Million - $4.79 Million
704,990 Added 37.28%
2,595,919 $16.9 Million
Q1 2022

May 16, 2022

BUY
$5.05 - $7.7 $7.43 Million - $11.3 Million
1,471,745 Added 351.1%
1,890,929 $9.55 Million
Q4 2021

Feb 14, 2022

BUY
$7.13 - $15.19 $965,273 - $2.06 Million
135,382 Added 47.7%
419,184 $3.24 Million
Q3 2021

Nov 15, 2021

BUY
$11.0 - $17.95 $3.12 Million - $5.09 Million
283,802 New
283,802 $4.2 Million

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $302M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.